Page last updated: 2024-12-11
t 3762
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
T 3762: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6918232 |
| SCHEMBL ID | 4442183 |
| MeSH ID | M0293702 |
Synonyms (54)
| Synonym |
|---|
| pazufloxacin mesilate |
| gm-1172 |
| pasil |
| pazucross |
| t-3762 |
| D05382 |
| pazufloxacin mesilate (jp17) |
| pasil (tn) |
| pazufloxacin methanesulfonate |
| 163680-77-1 |
| HMS3264I18 |
| P1962 |
| pazufloxacin mesylate |
| 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (s)-, monomethanesulfonate |
| t 3762 |
| nsc 759831 |
| 2xi226j1hs , |
| unii-2xi226j1hs |
| nsc759831 |
| pharmakon1600-01502319 |
| nsc-759831 |
| S3621 |
| AKOS015895384 |
| AKOS015852496 |
| CCG-213820 |
| (-)-(3s)-10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid methanesulphonate |
| pazufloxacin mesilate [who-dd] |
| pazufloxacin mesilate [jan] |
| (-)-(3s)-10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid methanesulfonate |
| pazufloxacin methanesulfonate [mi] |
| pazufloxacin mesilate [mart.] |
| CS-4497 |
| SCHEMBL4442183 |
| pazufloxacinamesilate, antibiotic for culture media use only |
| Q-101928 |
| pazufloxacin (mesylate) |
| HY-B0724A |
| mfcd00913262 |
| DTXSID80167645 |
| pazufloxacin mesilate, vetranal(tm), analytical standard |
| pazufloxaxin methanesulfonate |
| pazufloxacinmesylate |
| (2s)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; methanesulfonic acid |
| (s)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid compound with methanesulfonic acid (1:1) |
| BCP11980 |
| AMY18115 |
| (s)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid methanesulfonic acid salt |
| 7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3s)-, methanesulfonate (1:1) |
| Q27255767 |
| (2s)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid;methanesulfonic acid |
| pazufloxacin mesylate 100 microg/ml in acetonitrile |
| EN300-6733488 |
| (2s)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0,5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid; methanesulfonic acid |
| Z3234818655 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "To predict the actions of T-3762, a newly developed fluoroquinolone antimicrobial agent, as well as ciprofloxacin (CPFX) and ofloxacin (OFLX), on injection sites when dosed parenterally, their ability to increase cutaneous vascular permeability in dogs and to release histamine from rat peritoneal mast cells was examined." | ( Histamine-releasing properties of T-3762, a novel fluoroquinolone antimicrobial agent in intravenous use. II. Dermovascular permeability-increasing effect and action on peritoneal mast cells. Arai, H; Fukuda, Y; Furuhata, K; Narita, H; Soumi, K; Watanabe, Y, 1998) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.37
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||